| Phase 14 trials |
|
Phase 1
|
NCT06908577 |
Apr → Nov 2025 |
— |
AstraZeneca |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06304961 |
Apr → Sep 2024 |
— |
AstraZeneca |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05070312 |
Aug 2021 → Feb 2022 |
— |
AstraZeneca |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03096795 |
May 2017 → Sep 2019 |
chronic obstructive pulmonary disease |
MedImmune LLC |
Completed
|
No outcome recorded
|
| Phase 26 trials |
|
Phase 2
|
NCT06897748 |
Apr 2025 → Apr 2026 |
chronic obstructive pulmonary disease |
AstraZeneca |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT06932263 |
Mar 2025 → Jun 2027 expected |
asthma |
AstraZeneca |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT04631016 |
Dec 2020 → May 2023 |
chronic bronchitis |
AstraZeneca |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT04570657 |
Sep 2020 → Dec 2022 |
asthma |
AstraZeneca |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT04212169 |
Dec 2019 → Jul 2022 |
atopic eczema |
AstraZeneca |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT04170543 |
Nov 2019 → May 2023 |
diabetic kidney disease |
AstraZeneca |
Completed
|
No outcome recorded
|
| Phase 36 trials |
|
Phase 3
|
NCT07566195 |
May 2026 → Dec 2028 expected |
chronic obstructive pulmonary disease |
AstraZeneca |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06040086 |
Sep 2023 → Mar 2026 overdue |
chronic obstructive pulmonary disease |
AstraZeneca |
Active not recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT05742802 |
Mar 2023 → Feb 2026 |
chronic obstructive pulmonary disease |
AstraZeneca |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT05624450 |
Dec 2022 → Jun 2026 overdue |
acute respiratory failure |
AstraZeneca |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT05158387 |
Feb 2022 → Jan 2026 |
chronic obstructive pulmonary disease |
AstraZeneca |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT05166889 |
Jan 2022 → Jan 2026 |
chronic obstructive pulmonary disease |
AstraZeneca |
Completed
|
No outcome recorded
|